MetaCap

Journey Medical (DERM) vs NRX Pharmaceuticals (NRXP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NRX Pharmaceuticals (NRXP) has outperformed Journey Medical (DERM) over the past year, gaining 0.9% versus a loss of 55.8%. Over five years, DERM leads with a -61.1% price change compared with -96.8% for NRXP. NRX Pharmaceuticals is the larger company by market cap ($95.3 million vs $93.2 million), about 1.0 times the size.

Journey Medical converts more of its revenue into profit, with a net margin of -18.5% versus -2336.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DERM-55.76%NRXP+0.94%
+126%+31%-64%
Nov 21, 20251 yearNov 20, 2026
DERM-62.46%NRXP-95.81%
+38%-33%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DERM versus NRXP key metrics
MetricDERMNRXP
Share price$3.30$2.15
Market cap$93.16M$95.31M
1-day change-7.04%-15.69%
YTD return-57.20%-20.66%
1-year return-55.76%+0.94%
5-year return-61.13%-96.81%
EPS (TTM)$-0.18$-0.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$61.86M$1.23M
Revenue growth (YoY)+10.20%—
Net income (latest FY)$-11.43M$-28.62M
Gross margin66.17%58.78%
Operating margin-13.21%-1324.41%
Net margin-18.48%-2336.49%
52-week high$9.56$5.06
52-week low$3.21$1.62
Distance from 52-week high-65.46%-57.47%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+286.36%+1702.33%
Average volume190.39K1.07M
Shares outstanding22.23M44.33M
Employees5829
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NRXP has outperformed DERM by 56.7 percentage points over the past year.
  • Journey Medical is more profitable, keeping -18.5 cents of every revenue dollar as net income versus -2336.5 cents for NRX Pharmaceuticals.

About Journey Medical

DERM stock →

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees

About NRX Pharmaceuticals

NRXP stock →

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

DERM vs NRXP FAQ

Which is bigger, Journey Medical or NRX Pharmaceuticals?

NRX Pharmaceuticals (NRXP) is larger, with a market capitalization of $95.31M compared with $93.16M for Journey Medical (DERM).

Which stock has performed better over the past year, DERM or NRXP?

NRXP returned +0.94% over the past 12 months, compared with -55.76% for DERM (price return, excluding dividends). Past performance does not predict future results.

Are Journey Medical and NRX Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons